"Chronic Psychotic". Psychotic disorder with hallucinations due to known physiological condition
Conditions
Interventions
Intervention 1: Intervention Group: Participants will receive oral rivastigmine capsules (Novartis, Exelon), starting at 3 mg once daily with food during the first week. The dose will be increased by
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Diagnosis of psychotic disorder based on DSM-5 criteria Age between 18 and 65 years Presence of prominent negative symptoms (based on the PANSS scale)
Exclusion criteria
Exclusion criteria: Drug Interactions Participation in other studies (experimental treatments within last 3 months) pregnancy or lactation severe cognitive impairment (MMSE =18)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative Symptoms Score. Timepoint: Before the intervention, at the mid-point (6 weeks after the start), and at the end of the period (12 weeks after the start). Method of measurement: **Standard Questionnaire for Positive and Negative Symptoms Scale (PANSS)**.;Drug side effects (nausea, vomiting, itching, etc.). Timepoint: Before the intervention, at the mid-point (6 weeks after the start), and at the end of the period (12 weeks after the start). Method of measurement: History and Examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactdr. Fatemeh Rezaie
Zahedan University of Medical Sciences
Outcome results
None listed